Apalutamide delays progression of nonmetastatic, castration-resistant prostate cancer

A multi-institutional phase 3 trial found that treatment with an investigational androgen receptor inhibitor significantly delayed the development of metastasis in patients with prostate cancer that had become resistant to standard androgen-deprivation therapy.

from Top Health News -- ScienceDaily http://ift.tt/2nP2DHG